Voyager Therapeutics, Inc. Share Price & Technical Analysis
VYGR · $3.80 (+3.26%)
Healthcare / Biotechnology
$3.80
+3.26%
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-as…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, 14% avg return in past 3 year May month.
-5% return in 2026, -2% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | 5% | -2% | -5% | 0% | – | – | – | – | – | – | – | -5% |
| 25 | -5% | -21% | -17% | 9% | -25% | -3% | 3% | 6% | 42% | 2% | -13% | -2% | -24% |
| 24 | -30% | 14% | 12% | -19% | 8% | -7% | 16% | -28% | -11% | 17% | 1% | -20% | -46% |
| 23 | 52% | -24% | 7% | -6% | 58% | 0% | -19% | 8% | -23% | -14% | 11% | 15% | 63% |
| 22 | 7% | 38% | 90% | -5% | -16% | -3% | 14% | -10% | 0% | -12% | 11% | 3% | 116% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$248.63M
P/E ratio
—
52W high
$5.55
52W low
$2.65
Volume
5,71,611
Beta
1.26
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Voyager Therapeutics, Inc. share price today?
- Voyager Therapeutics, Inc. (VYGR) last traded around $3.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VYGR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VYGR. Download the app for real-time alerts.
- How can I analyze Voyager Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.